Brought to you by 
Series A venture round brings in $6mm for OvaScience
05 Apr 2012
Executive Summary
Newly formed female infertility treatment company OvaScience has raised $6mm through its Series A venture round from Longwood Fund and Bessemer Venture Partners. The company was created to develop AUGMENT (AUtologous Germline Mitrochondrial ENergy Transfer) to improve the success of in vitro fertilization. AUGMENT involves the injection of a woman’s own egg-precursor cells (obtained from ovarian tissue) into eggs to revitalize the mitochondria that typically declines with age.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A venture round brings in $6mm for OvaScience
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice